GLP-1 enthusiasm pushes BioAge Labs into new age with $170M series D

Until last year, BioAge Labs’ progress could be best described as a slow burn, with a pipeline of longevity-focused medicines taking shape incrementally but consistently.  | The frenzy around GLP-1s has changed BioAge’s trajectory, as its one of a select few biotechs with a combo candidate that might enhance weight loss without muscle loss.

Source: GLP-1 enthusiasm pushes BioAge Labs into new age with $170M series D